For investors
Diligence the trial like an operator.
Venture, private equity, or public markets: get an independent, fully cited feasibility read on any clinical-stage asset — probability of success, comparable-trial failures, patent runway, valuation — in hours, from public data alone.
Probability of success, grounded in base rates and cited evidence.
The problem
The scientific story is the easy part. The trial is where theses die.
Most clinical-stage bets fail on execution — enrollment that never materialises, a design weaker than the indication norm, a readout priced for perfection. That risk is legible in public data, if someone does the operator's work of reading it.
What you get
An operator's read, at diligence speed.
Independent probability of success
A probability grounded in published industry base rates for the phase and therapeutic area, adjusted for what the assessment found about this specific trial — presented with its assumptions and sources, never as a black-box score.
Why comparable trials failed
Every comparable trial in the indication, with an honest read of which succeeded, which failed, and why — the base-rate reality behind the management narrative.
Risk-adjusted valuation
Market sizing, value-based pricing against the standard of care, and a risk-adjusted eNPV you can stress in your own model — each input cited.
Patent & exclusivity runway
The patent landscape around the asset and its class, and how much exclusivity is actually left when the trial reads out.
Delay & catalyst signals
A scanner over SEC filings and earnings calls for timeline slippage the press release didn’t mention, alongside adverse-event signals from public safety data.
Enrollment reality check
Eligible-patient reach, eligibility complexity, and site density against competing trials — whether the enrollment timeline management is guiding to is physically possible.
Diligence workflow
From asset name to committee memo.
Name the asset
A molecule (or just its drug class) and an indication is enough — no confidential data room required. The assessment is built entirely from public sources.
The engine builds the case
Around 50 live public sources — trial registries, literature, FDA and EMA precedent, patents, pricing, SEC filings — are pulled and scored across six pillars, every number cited.
Take it to the committee
A go/no-go verdict and a decision memo you can put in front of an investment committee — where every challenged number resolves to a public record, not to “the model said so.”
Decision-support — not investment advice
Put an operator's read in your next memo.
Tell us the asset and the indication. We'll run a full cited assessment and walk you through it — every number traceable to the public record it came from.